Target Price | $158.10 |
Price | $138.31 |
Potential | 14.31% |
Number of Estimates | 34 |
34 Analysts have issued a price target Arm 2026 . The average Arm target price is $158.10. This is 14.31% higher than the current stock price. The highest price target is $220.50 59.42% , the lowest is $77.31 44.11% . | |
A rating was issued by 42 analysts: 24 Analysts recommend Arm to buy, 15 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Arm stock has an average upside potential 2026 of 14.31% . Most analysts recommend the Arm stock at Purchase. |
38 Analysts have issued a sales forecast Arm 2026 . The average Arm sales estimate is $4.8b . This is 17.18% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $6.1b 46.98% , the lowest is $4.4b 5.58% .
This results in the following potential growth metrics:
2025 | $4.0b | 23.94% |
---|---|---|
2026 | $4.8b | 20.51% |
2027 | $5.9b | 21.39% |
2028 | $7.0b | 18.66% |
2029 | $9.1b | 30.20% |
2030 | $11.7b | 29.57% |
2031 | $15.4b | 31.42% |
2032 | $14.6b | 5.06% |
27 Analysts have issued an Arm EBITDA forecast 2026. The average Arm EBITDA estimate is $2.3b . This is 140.19% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 202.91% , the lowest is $1.8b 87.95% .
This results in the following potential growth metrics and future EBITDA Margins:
2025 | $916m | 364.97% |
---|---|---|
2026 | $2.3b | 152.51% |
2027 | $3.0b | 30.09% |
2028 | $4.0b | 32.70% |
2029 | $5.1b | 26.47% |
2030 | $6.0b | 19.45% |
2031 | $7.6b | 25.76% |
2025 | 22.86% | 275.16% |
---|---|---|
2026 | 47.90% | 109.54% |
2027 | 51.33% | 7.16% |
2028 | 57.40% | 11.83% |
2029 | 55.76% | 2.86% |
2030 | 51.40% | 7.82% |
2031 | 49.19% | 4.30% |
37 Analysts have issued a Arm forecast for earnings per share. The average Arm EPS is $1.72 . This is 160.61% higher than earnings per share in the financial year 2025. The highest EPS forecast is $2.23 237.88% , the lowest is $1.40 112.12% .
This results in the following potential growth metrics and future valuations:
2025 | $0.75 | 158.62% |
---|---|---|
2026 | $1.72 | 129.33% |
2027 | $2.28 | 32.56% |
2028 | $2.87 | 25.88% |
2029 | $3.69 | 28.57% |
2030 | $4.59 | 24.39% |
2031 | $5.64 | 22.88% |
2032 | $5.40 | 4.26% |
Current | 209.56 | 39.74% |
---|---|---|
2026 | 80.57 | 61.55% |
2027 | 60.56 | 24.84% |
2028 | 48.21 | 20.39% |
2029 | 37.45 | 22.32% |
2030 | 30.16 | 19.47% |
2031 | 24.54 | 18.63% |
2032 | 25.60 | 4.32% |
Based on analysts' sales estimates for 2026, the Arm stock is valued at an EV/Sales of 30.66 and an P/S ratio of 31.26 .
This results in the following potential growth metrics and future valuations:
Current | 35.93 | 10.04% |
---|---|---|
2026 | 30.66 | 14.66% |
2027 | 25.26 | 17.62% |
2028 | 21.29 | 15.73% |
2029 | 16.35 | 23.20% |
2030 | 12.62 | 22.82% |
2031 | 9.60 | 23.91% |
2032 | 10.11 | 5.33% |
Current | 36.63 | 9.88% |
---|---|---|
2026 | 31.26 | 14.66% |
2027 | 25.75 | 17.62% |
2028 | 21.70 | 15.73% |
2029 | 16.67 | 23.20% |
2030 | 12.86 | 22.82% |
2031 | 9.79 | 23.91% |
2032 | 10.31 | 5.33% |
Analyst | Rating | Action | Date |
---|---|---|---|
Seaport Global |
➜
Buy
|
Initiated | Aug 11 2025 |
UBS |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Raymond James |
Outperform
➜
Outperform
|
Unchanged | Jul 31 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Rosenblatt |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Jul 31 2025 |
Analyst Rating | Date |
---|---|
Initiated
Seaport Global:
➜
Buy
|
Aug 11 2025 |
Unchanged
UBS:
Buy
➜
Buy
|
Jul 31 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 31 2025 |
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Jul 31 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 31 2025 |
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Jul 31 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Jul 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.